Review article · 2026 · Open access

Organs-on-Chips in Drug Development: Engineering Foundations, Artificial Intelligence, and Clinical Translation

Nilanjan Roy, Luca Cucullo

Biosensors, 16(3), 155 · Published 11 March 2026 · DOI 10.3390/bios16030155

Open PDFView at the publisherCite this paper

In brief

“Organs-on-Chips in Drug Development: Engineering Foundations, Artificial Intelligence, and Clinical Translation” is a 2026 review article by Nilanjan Roy and Luca Cucullo, published in Biosensors. OpenAlex counts 22 citations as of 19 November 2026, which puts it in the top 1% of works published in 2026 by citations. It is open access under a CC BY licence: the full text is free to read at Biosensors.

Citations
22
Most cited in
2026 (22)
Field-weighted impact
8.64
References
132
Authors
2

Abstract

Organ-on-a-chip (OoC) technologies, also termed microphysiological systems (MPSs), integrate microfluidics, engineered biomaterials, human-derived cells, and on-chip biosensing to model human physiology in microscale devices that deliver quantitative, time-resolved readouts. This review surveys the 2010-2025 literature, emphasizing how sensing, standardized sampling, and analytics enable clinical concordance and fit-for-purpose regulatory use. We synthesize advances in (i) materials, fabrication, and microfluidic design; (ii) organ- and disease-focused case studies; and (iii) translational benchmarks that align chip outputs with clinical pharmacokinetics, toxicology, and biomarker datasets. Across organ systems, platforms increasingly incorporate vascularization, immune components, and organoid hybrids, paired with real-time measurements of barrier integrity, metabolism, electrophysiology, and secreted biomarkers using impedance (TEER), electrochemical, and optical modalities. Representative benchmarking studies report cardiac OoCs achieving AUROC ≥ 0.85 for torsadogenic risk classification, and renal chips improving prediction of transporter-mediated clearance relative to conventional in vitro assays. We summarize validation approaches and regulatory developments relevant to new approach methodologies, including the FDA Modernization Act 2.0, and discuss how AI and multi-omics can automate signal and image analysis, harmonize cross-platform datasets, and support digital-twin workflows that couple OoC measurements to in silico models. Overall, biosensor-enabled OoCs are progressing toward quantitatively benchmarked platforms for safety pharmacology, ADME/PK-PD, and precision medicine.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Roy, N., & Cucullo, L. (2026). Organs-on-Chips in Drug Development: Engineering Foundations, Artificial Intelligence, and Clinical Translation. Biosensors, 16(3), 155. https://doi.org/10.3390/bios16030155

MLA 9

Roy, Nilanjan, and Luca Cucullo. “Organs-on-Chips in Drug Development: Engineering Foundations, Artificial Intelligence, and Clinical Translation.” Biosensors, vol. 16, no. 3, 2026, p. 155. https://doi.org/10.3390/bios16030155.

Chicago

Roy, Nilanjan and Luca Cucullo. 2026. “Organs-on-Chips in Drug Development: Engineering Foundations, Artificial Intelligence, and Clinical Translation.” Biosensors 16 (3): 155. https://doi.org/10.3390/bios16030155.

Harvard

Roy, N. and Cucullo, L. (2026) ‘Organs-on-Chips in Drug Development: Engineering Foundations, Artificial Intelligence, and Clinical Translation’, Biosensors, 16(3), p. 155. doi:10.3390/bios16030155.

IEEE

N. Roy and L. Cucullo, “Organs-on-Chips in Drug Development: Engineering Foundations, Artificial Intelligence, and Clinical Translation,” Biosensors, vol. 16, no. 3, p. 155, 2026, doi: 10.3390/bios16030155.

BibTeX

@article{roy2026organs,
  title     = {{Organs-on-Chips in Drug Development: Engineering Foundations, Artificial Intelligence, and Clinical Translation}},
  author    = {Roy, Nilanjan and Cucullo, Luca},
  journal   = {Biosensors},
  year      = {2026},
  volume    = {16},
  number    = {3},
  pages     = {155},
  doi       = {10.3390/bios16030155},
  url       = {https://doi.org/10.3390/bios16030155}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research

  • organ-on-a-chip
  • microphysiological systems
  • drug development
  • microfluidics
  • engineered biomaterials
  • on-chip biosensing
  • organoids
  • vascularization

Work with this paper

Most-cited papers in Engineering

All highly cited Engineering papers

Questions about this paper

How do I cite this paper in APA style?

Roy, N., & Cucullo, L. (2026). Organs-on-Chips in Drug Development: Engineering Foundations, Artificial Intelligence, and Clinical Translation. Biosensors, 16(3), 155. https://doi.org/10.3390/bios16030155

How many times has this paper been cited?

22 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Biosensors: sign in and open the PDF from this page.

Who wrote this paper?

Nilanjan Roy, Luca Cucullo.

What is the DOI of this paper?

10.3390/bios16030155, permanently at https://doi.org/10.3390/bios16030155. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.